Santander Agrees to Buy Sabadell's UK Unit TSB for £2.7 Billion
Save
Banco Sabadell SA has agreed to sell its UK unit to Banco Santander SA for £2.65 billion ($3.63 billion), according to people familiar with the matter.
Spokespeople for Sabadell and Santander declined to comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
mAbxience Announces European Commission Approval of Denosumab Biosimilars
MADRID, July 2, 2025 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce® and Izamby®. This approval follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) and represents a major milestone in mAbxience's mission to provide high-quality, accessible, and affordable therapies worldwide. Denbrayce®, referencing Amgen's Xgeva®, is indicated for the prevention of skeletal-related events in adults with advanced malignancies involving bone, as well as for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone. Izamby®, referencing Amgen's Prolia®, is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, a condition that causes bones to become weak and more prone to breaking. "This approval is a testament to mAbxience's dedication to scientific excellence and our commitment to broadening access to essential biologic therapies," said Jurgen Van Broeck, CEO of mAbxience. "We are proud to contribute to reducing the burden of osteoporosis, cancer-related bone conditions, and rare bone diseases in Europe. This milestone brings us one step closer to ensuring that more patients across Europe can benefit from high-quality, affordable treatment options." Denosumab is a human monoclonal antibody that works by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL), thereby preventing the development of osteoclasts, the cells responsible for bone breakdown. It is a well-established treatment for osteoporosis, treatment-induced bone loss, bone metastases, and giant cell tumor of bone. With the approval of these biosimilars mAbxience further demonstrates its expertise in the development and production of biosimilars, reinforcing its contribution to improving patient access to life-changing therapies and supporting the sustainability of healthcare systems across Europe. This approval marks another important step in mAbxience's mission to provide affordable, accessible and life-changing therapies worldwide. With a robust pipeline and a growing network of partners, mAbxience continues to enhance patient access to advanced treatments while supporting healthcare systems in managing the rising costs of biologic medicines. About mAbxience mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. In August 2022, Fresenius Kabi and Insud Pharma entered into an agreement whereby Fresenius Kabi, an operating company of Fresenius, acquired a majority stake of mAbxience, making it a global, vertically integrated biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website ( or connect with us on LinkedIn. Photo: View original content to download multimedia: SOURCE mAbxience Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Eurozone's Jobless Rate Creeps Higher as Business Uncertainty Abounds
The eurozone's unemployment rate inched higher in May, a sign of jitters among European firms amid economic uncertainty over tariffs and geopolitical tensions. Unemployment rose to 6.3% in the 20-nation currency area, up from 6.2% in April, the European Union's statistics agency Eurostat said Wednesday. A consensus of economists polled by The Wall Street Journal had expected the rate to hold at 6.2% in May. Private Equity Caught in Crosshairs of Elise Stefanik's Attack on Harvard China Is Quickly Eroding America's Lead in the Global AI Race Lululemon Sues Costco Over Alleged Knockoff Activewear Trump Said 'No Tax on Social Security.' The Tax Bill Comes Closer to It. The Tech-Stock Bargains Hiding in Nvidia's Shadow Despite the uptick, the jobless rate is near historically tight levels. April's level equaled the eurozone's record-low rate, although it came after March's level had been revised higher to 6.4%. The rise in May was driven by Italy, where the rate rose to 6.5% from 6.1% in April, although the unemployment level there has been volatile. However, uncertainty in the economic outlook suggests more volatility in the labor market to come. The raising of trade barriers by the Trump administration and rising oil prices amid continued geopolitical upheaval in the Middle East mean companies have sometimes struggled to plan ahead, preferring to hold onto staff rather than to hire new ones. President Trump has set a July 9 deadline for trade talks between the EU and U.S. to agree on a deal. The U.S. has placed 25% tariffs on cars and 50% on steel and aluminum, with a 10% baseline on most other goods imports into the U.S. Trump has threatened a 50% tariff on all EU goods imports should talks end without an agreement. Some major European manufacturers such as carmaker Audi, technology company Siemens and industrial conglomerate Thyssenkrupp have pledged in recent months to reduce their workforces as they reconfigure to the global economic uncertainty and also the transition to electric vehicles. While business expectations in Europe's manufacturing sector improved in more timely data for June, it didn't prevent further cutbacks to employment, according to a survey of firms published Monday. The rate of job shedding was slightly faster in June than May, the S&P Global report said. However, overall employment in the eurozone was marginally up, given jobs growth in the services sector where staffing levels were up modestly, S&P said in a separate report last week. Meanwhile, the surge in spending promised by Germany's new government is expected to provide a stimulus to growth within the eurozone's largest economy. Some economists believe that underused parts of the factory sector could be repurposed for weapons manufacturing. Labor market shortages persist, as ING economist Bert Colijn noted in a client update, and while vacancy rates are falling, they are still far higher than before 2018. That would otherwise cause concern for the European Central Bank as it tries to control inflation, given the likelihood that a tight labor market would engender strong wage growth. But productivity growth in the eurozone is picking up, meaning that inflationary pressures from the jobs market are actually fading and should align with the ECB's 2% inflation target, Colijn continued. The ECB expects unemployment to average 6.3% in 2025, according to its latest projections. However, it said there could be a renewed decline in the rate from early next year should economic growth accelerate as it anticipates. Write to Ed Frankl at JPMorgan Chase Ups Dividend, Approves $50 Billion Buyback After Stress Test Powell Cites Solid Economy in Keeping Wait-and-See Stance on Rates Car Sales Cooled in June as Trump Bump Fades Hollywood Confronts AI Copyright Chaos in Washington, Courts Tech Stocks Fall, Led by Tesla, and the Market Slips From All-Time High Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Britain's Starmer backs his Treasury chief after U-turns dent the government's fiscal plans
LONDON (AP) — British Prime Minister Keir Starmer's office said Wednesday that Treasury chief Rachel Reeves is secure in her job after a series of government U-turns dented her revenue-raising plans. Speculation about Reeves' future mounted after she appeared to be in tears Wednesday in the House of Commons, the day after an embarrassing reversal for the government over its plans to cut welfare spending. Many viewers observed that Reeves looked exhausted and upset as she sat behind Starmer during the weekly Prime Minister's Questions session. The Treasury said Reeves was dealing with a 'personal matter.' It would not elaborate. Starmer initially declined to say, when asked by opposition leader Kemi Badenoch, that Reeves would still have her job when the next election is called, likely in 2029. But Starmer's press secretary later said Reeves 'is going nowhere. She has the prime minister's full backing.' On Tuesday, Starmer's government was forced to water down plans to curb welfare spending in order to quell a rebellion by lawmakers from his own party. In something of a hollow victory, the bill passed its first big House of Commons hurdle after the government appeased Labour Party rebels by softening and delaying cuts to welfare benefits for disabled people. Even so, 49 Labour lawmakers voted against the bill. The result is a major blow to Starmer's authority as he approaches the one-year anniversary of his election on Friday, reckoning with a sluggish economy and rock-bottom approval ratings. It also leaves the Treasury short of money it had counted on to invest in public services, making tax increases more likely. The government has promised not to raise key levies including income tax and sales tax. The government estimated that its welfare reforms would save 5 billion pounds ($7 billion) a year, but after the changes it's unclear whether they will save any money at all. The reversal follows a decision in May to drop a plan to end winter home heating subsidies for millions of retirees, which Reeves had also counted on to raise money. Jill Lawless, The Associated Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
